TITLE

BIOWA LICENSES POTELLIGENT TECHNOLOGY TO SANOFI-AVENTIS

PUB. DATE
May 2009
SOURCE
Worldwide Biotech;May2009, Vol. 21 Issue 5, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on a license agreement signed by BioWa Inc. with sanofi-aventis in 2009. The agreement will provide the global healthcare company with access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapies. Masamichi Koike, president and chief executive officer (CEO) of BioWa, explained the benefits of the agreement to the company.
ACCESSION #
38216165

 

Related Articles

  • Sanoti-aventis Enters Consumer Healthcare Market in China.  // Nutraceuticals World;Mar2010 Part 1, Vol. 13 Issue 2, p20 

    The article reports on the agreement signed by France's Sanofi-Aventis SA with Minsheng Pharmaceutical Co. Ltd. to form a new consumer healthcare joint venture in China in 2010

  • Sanofi, Lexicon collaborate on sotagliflozin.  // Chain Drug Review;11/23/2015, Vol. 37 Issue 19, p17 

    The article reports that drug companies Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of the investigational oral dual inhibitor sotagliflozin.

  • Sanofi-Aventis signs licensing agreement with CureDM.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p16 

    The article reports on the licensing agreement signed by Sanofi-Aventis and CureDM Inc. on a novel human peptide Pancreate that could restore a patient's ability in producing insulin and other pancreatic hormones in both type 1 and type 2 diabetes. It states that under the agreement,...

  • Deal watch: CureDM licenses regenerative diabetes therapy to Sanofi–Aventis.  // Nature Reviews Drug Discovery;Jun2010, Vol. 9 Issue 6, p422 

    The article reports on the agreement between the Sanofi-Aventis and CureDM Inc. It says that Sanofi-Aventis has received the exclusive worldwide rights from CureDM for the development and marketing of the first-in-class peptide therapeutic Pancreate, which will be used to treat type 1 and type 2...

  • Sanofi Adds Glenmark Antibody to Portfolio for Potential $613M. Shaffer, Catherine // BioWorld International;5/18/2011, Vol. 16 Issue 20, p1 

    The article reports on the licensing of a monoclonal antibody known as GBR 500 by Glenmark Pharmaceuticals SA, a subsidiary of India-based Glenmark Pharmaceuticals Ltd., to Sanofi-Aventis SA in Paris, France. It says that the deal includes an advance payment of 50 million U.S. dollars and...

  • Merrimack Snags $530M Cancer Antibody Partnership with Sanofi. Young, Donna // BioWorld Today;10/2/2009, Vol. 20 Issue 190, p1 

    The article reports on a licensing deal between Merrimack Pharmaceuticals Inc. and Sanofi-Aventis Group SA amounting to 60 million U.S. dollars upfront and 470 million U.S. dollars in milestone payments. The deal concerns the development of MM-121, an ErbB3 receptor blocker being tested for the...

  • Exelixis Shares Soar on $1B Sanofi Drug Deal.  // Bioworld Week;6/1/2009, Vol. 17 Issue 22, p1 

    The article announces that Exelixis Inc. has signed up a new licensing and discovery agreement with Sanofi-Aventis SA on May 28, 2009. The deal is intended to push shares of about 18.8% to $5.36 for phosphoinositide-3 kinase (PI3K) inhibitors targeting cancer. As part of the deal, Exelixis will...

  • Dyax Signs Sanofi to Potential $500M Deal.  // Bioworld Week;2/18/2008, Vol. 16 Issue 7, p3 

    The article reports on the partnership agreed between Dyax Corp. and Sanofi-Aventis SA. It states that the agreement provides Sanofi the authority to develop and commercialize Dyax's preclinical cancer antibody DX 2240 as well as utilize its antibody phage display technology. It reveals that the...

  • Sanofi-Aventis and Ascenta Therapeutics sign licensing agreement.  // PharmaWatch: Cancer;Jul2010, Vol. 9 Issue 7, p17 

    The article reports on the licensing agreement signed between French pharmaceutical company Sanofi-Aventis SA and U.S.-based pharmaceutical company Ascenta Therapeutics Inc. The agreement calls for an exclusive global collaboration and licensing agreement on compounds that restore tumor cell...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics